Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Novo Nordisk’s latest update on its obesity pipeline centers on a Phase 3 study officially titled “Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity.” The study aims to see how well the company’s new drug combo, CagriSema, helps people lose weight compared to Eli Lilly’s rival drug tirzepatide. This is important because it directly pits Novo Nordisk’s next-generation obesity therapy against a leading competitor, with results that could shift long-term expectations for the obesity market.
The study tests two active weekly injection treatments. One group receives CagriSema, a fixed-dose combination of cagrilintide and semaglutide, both given under the skin. The other group receives tirzepatide, also a weekly under-the-skin injection. Both are designed to support significant weight loss in people living with obesity, but CagriSema is still experimental and not yet approved for routine use.
The trial is an interventional, randomized Phase 3 study with two parallel treatment arms. Participants are randomly assigned to either CagriSema or tirzepatide, with no placebo arm. There is no masking, meaning both investigators and participants know which drug is being given. The main purpose is treatment, focusing on how much weight people lose and how well they tolerate the drugs over the course of the study.
The study was first submitted in November 2023, with treatment lasting around a year and a half for each participant, including a gradual dose build-up and a long maintenance period. The trial status is now listed as completed, and the last update on the record was posted on February 5, 2026. While results are not yet posted, this recent update signals that the data collection phase is finished and that headline outcomes could follow in the near term.
For investors, this update matters because it moves Novo Nordisk one step closer to knowing whether CagriSema can match or beat tirzepatide on weight loss and safety. If CagriSema shows equal or better results, it could strengthen Novo Nordisk’s lead in obesity treatments and support continued revenue growth beyond current semaglutide products. A strong readout would likely be seen as a positive catalyst for NVO, while disappointing data could shift sentiment in favor of Eli Lilly and other competitors in the obesity space. Given the size of the market and high expectations already priced into obesity leaders, any comparative data from this study could trigger meaningful stock moves once released.
The study is now completed with its record recently updated, and further details will be available on the ClinicalTrials portal as results are posted.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.